Alkermes plc (NASDAQ:ALKS) Receives Consensus Rating of “Moderate Buy” from Analysts

Alkermes plc (NASDAQ:ALKS) has garnered a consensus "Moderate Buy" rating from 16 research firms, with an average 12-month price target of $44.15, following several analyst upgrades and new "Buy" or "Outperform" initiations. The biopharmaceutical company recently reported strong Q3 earnings, beating consensus with $0.49 EPS and $394.19 million in revenue, a 4.3% year-over-year increase. With institutional investors holding 95.21% of its stock and the company providing FY 2025 EPS guidance of $1.36-$1.47, the outlook appears positive for its portfolio addressing various medical needs.

Analysis

Alkermes plc (NASDAQ:ALKS) has garnered a strong consensus "Moderate Buy" rating from sixteen research firms, with eleven recommending "Buy" and two "Strong Buy." The average twelve-month price target stands at $44.15, notably above its recent opening price of $30.70, reflecting significant analyst confidence. Recent upgrades include Royal Bank of Canada boosting its target to $47.00 and Mizuho to $45.00, both maintaining "outperform" ratings.

The company reported robust Q3 earnings, with EPS of $0.49, exceeding consensus estimates of $0.41 by $0.08. Revenue reached $394.19 million, surpassing analyst forecasts of $355.23 million and marking a 4.3% year-over-year increase. Alkermes also provided a positive FY 2025 EPS guidance range of $1.36-$1.47, indicating anticipated future growth and operational efficiency.

Institutional investors and hedge funds collectively own a substantial 95.21% of Alkermes' stock, with several firms increasing their stakes in recent quarters, signaling strong institutional conviction. The stock trades at a P/E ratio of 15.20 and a PEG ratio of 1.70, suggesting a reasonable valuation relative to its growth prospects and industry peers. Its beta of 0.54 indicates lower volatility compared to the broader market, offering a degree of stability.

Key Decisions for Investors

• Investors should consider the strong analyst consensus and recent target price upgrades as indicators of potential upside, aligning with the company's positive Q3 earnings beat and favorable FY25 guidance.
• Evaluate the company's solid financial performance, including its 4.3% year-over-year revenue growth and strong margins, as evidence of fundamental strength in its biopharmaceutical operations.
• Monitor institutional ownership trends and the company's pipeline developments, particularly given the high institutional conviction and the biopharmaceutical sector's inherent growth drivers.